MultiLINK™ ADC Technology Suite
The MultiLINK™ ADC Technology Suite is a comprehensive toolbox with a versatile range of adaptable ADC linker and conjugation technologies – including next-gen dual payload capabilities – enabling the development of optimized, fit-for- purpose antibody-drug conjugates (ADCs).
In short
The MultiLINK™ ADC Technology Suite enables the selection of the right linker, chosen based on the antibody, payload, and targeting indication —to optimise the therapeutic potential of the ADC. Combined with our extensive ADC design and development experience, the suite accelerates the development of optimized, fit-for-purpose ADCs — driving faster development timelines and improved clinical outcomes.
With excellent antibody and payload compatibility, our versatile range of adaptable ADC linker and conjugation solutions allow for the optimisation of a range of key parameters–extending far beyond merely plasma stability and drug-to-antibody ratio (DAR) – enabling us to fine-tune pharmacokinetics for truly superior therapeutic performance
Debiopharm’s ADC Portfolio
Our value proposition
Our ADC portfolio consists of carefully selected targets with 1st-in-class or best-in-class potential, including Debio 1562M, a CD37-targeted ADC for the treatment of acute myeloid leukemia (AML) and Myelodysplastic syndromes (MDS), Debio 0532, an HER3-targeted ADC for solid tumors and Debio 0633, a potential first-in-class with a novel target. Key partnerships also comprise options to in-licence bispecific antibodies targeting HER2-HER3 and HER3-EGFR along with other further undisclosed targets. We are continuing to invest in our ADC platform, exploring potential game changing technologies such as novel and dual payloads, leveraging our solid development experience to accelerate ADC products to patients.
Our Ongoing Partnerships
